In one trial, ≥ Grade 3 neutropenia occurred in 42% of patients treated with the BCL‐2 inhibitor venetoclax (VEN) in combination with azacitidine versus 28% of those who received azacitidine and placebo [27]. Here, BCL2 is linked to neutropenia.